Möchten Sie immer auf dem neuesten Stand bleiben?

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated...

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Precision Medicine Collaboration and Licensing Deals 2019-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a...

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies,...

4D Path has announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials.

Trial analysis published in JNCI predicts residual cancer burden from baseline H&E slides using 4D Path's fully automated, treatment predictive platform

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the...

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its  planned regulatory submissions to Israel and Germany Company remains on...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell...

Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...